hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 05:39:45 - browse：68

Editor’s note: A recording of the event is embedded below.

Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?

Let’s dive in and discuss what to watch in the months ahead.

Speakers:

Alex Brill, CEO, Matrix Global Advisors
Chris Brown, managing partner and co-founder, Integrity Rx Partners
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
Thomas Newcomer, head of U.S. market access, Samsung Bioepis (sponsor speaker)

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Medical records are filled with copy

focus

WSS

Texas Medical Board asked to define abortion emergency exception

Anesthesiologist group: stop taking Ozempic before surgery

How to save PrEP access — and even expand it

Why Novartis is going to walk from its acquisition of MorphoSys

What’s missing from the debate over nursing home staff minimums

In age of alternative facts, a scholarly course on calling out crap

hotspot

hotspot

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

In age of alternative facts, a scholarly course on calling out crap

Affirmative action in medical school literally saved lives

What’s missing from the debate over nursing home staff minimums

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The CDC's new social media misinformation war

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare proposal to cover medical devices draws a mixed reaction

Trump demands the U.S. pay no more for drugs than other countries … again

In age of alternative facts, a scholarly course on calling out crap

hotspot

Johnson & Johnson sued for allegedly overpaying for workers' drugs

DIEP, the 'gold standard' of breast reconstruction, is under threat

Trump demands the U.S. pay no more for drugs than other countries … again

A single Democrat is willing to weaken Medicare negotiation power

Medical records are filled with copy

Cano Health’s bankruptcy is a warning for Medicare Advantage

Wikipedia

focus

entertainment

focus